Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings document the company’s activities as a dermatology-focused developer of topical drug products such as TWYNEO and EPSOLAY and pipeline candidates including SGT-610 and SGT-210.
On this page, you can review Sol-Gel’s Form 6-K submissions that furnish press releases and, in some cases, unaudited condensed consolidated financial statements for specific periods. These filings cover topics such as quarterly and semi-annual financial results, updates on the Phase 3 clinical trial of SGT-610 for Gorlin syndrome, developments in the Phase 1b study of SGT-210 in Darier disease, licensing and product purchase agreements for EPSOLAY and TWYNEO, and corporate actions like the 10-for-1 reverse share split and the transfer of the company’s listing to the Nasdaq Capital Market.
Sol-Gel’s filings also include proxy materials for annual shareholder meetings, auditor appointments, board and executive approvals and other governance matters. Certain press releases attached as exhibits to Form 6-K are expressly incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the filings. For investors analyzing SLGL, the 20-F annual report and accompanying risk factor discussions provide additional context on clinical, regulatory, financial and market risks associated with the company’s dermatology portfolio and rare disease programs.
Stock Titan’s SEC filings page for SLGL presents these documents with real-time updates from EDGAR and AI-powered summaries that highlight key points in lengthy disclosures. This helps readers quickly understand Sol-Gel’s financial position, clinical trial status, licensing arrangements and corporate actions without manually parsing every line of each 6-K or 20-F filing.
Sol-Gel Technologies Ltd. filed a Form 6-K as a foreign private issuer to furnish a press release issued on December 17, 2025. The press release provides an update following unblinding of the company’s Phase 1b study of SGT-210 in Darier Disease.
Exhibit 99.1, which contains the press release (other than its third paragraph), is incorporated by reference into Sol-Gel’s existing Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).
Opaleye Management Inc., reporting as a 10% owner of Sol-Gel Technologies Ltd., disclosed a small indirect purchase of ordinary shares. On 12/12/2025, 87 ordinary shares with a par value of NIS 1.00 per share were acquired at a reported price of $40. After this transaction, 371,795 ordinary shares are held indirectly through Opaleye, L.P. and 10,000 ordinary shares are held indirectly through a separately managed account. Opaleye Management Inc. states it may be deemed to beneficially own these securities through its roles with the fund and managed account, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Opaleye Management Inc. reported open market purchases of Sol-Gel Technologies Ltd. (SLGL) ordinary shares. On 11/24/2025, an affiliated fund bought 6 ordinary shares at $35.5 per share, and on 11/26/2025 it bought another 943 shares at a weighted average price of $40.00. Following these transactions, the fund is shown as beneficially owning 364,100 Sol-Gel ordinary shares, with an additional 10,000 shares held in a separately managed account. Opaleye Management Inc. states that it may be deemed to beneficially own these securities through its roles with the fund and the managed account and disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd. (SLGL) director Opaleye Management Inc. reported buying additional ordinary shares. On 11/20/2025, an affiliated fund purchased 5,784 ordinary shares at a weighted average price of $35.8305 per share in multiple trades within a price range of $35.132 to $36.10. After this transaction, Opaleye Management Inc. reports indirect beneficial ownership of 363,151 ordinary shares through Opaleye, L.P. and 10,000 ordinary shares through a separately managed account. The firm states it may be deemed to beneficially own these securities as investment manager and portfolio manager, while disclaiming beneficial ownership beyond its economic interest.
Sol-Gel Technologies Ltd. (SLGL) submitted a Form 6-K reporting that it issued a press release on November 20, 2025 announcing its financial results for the quarter ended September 30, 2025. The filing mainly serves to furnish this press release to investors.
Most of the press release, identified as Exhibit 99.1 (other than the two paragraphs immediately preceding the heading “Financial Results for the Third Quarter 2025”), is incorporated by reference into the company’s Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No. 333-286822).
Sol-Gel Technologies Ltd. (SLGL) received an initial ownership report from Opaleye Management Inc. as a 10% owner. The filing shows indirect beneficial ownership of 357,367 ordinary shares through Opaleye, L.P. and 10,000 ordinary shares through a separately managed account. Opaleye Management Inc. states it may be deemed to beneficially own these securities as investment manager and portfolio manager, but expressly disclaims beneficial ownership beyond its economic interest.
Sol-Gel Technologies Ltd. furnished a Notice of its 2025 Annual General Meeting and an accompanying proxy statement, together with a proxy card for shareholders of record as of September 29, 2025. The materials are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, ensuring the proxy disclosures are available to holders eligible to vote and to support related securities registrations. This filing supplies the formal voting materials shareholders need to review meeting matters and to submit proxies ahead of the meeting.
Sol-Gel Technologies Ltd. filed a report noting that it has received Health Canada approval for EPSOLAY®. This approval, announced in a company press release, represents official clearance for the product in the Canadian market. The filing also states that portions of the press release are incorporated by reference into Sol-Gel’s existing registration statements on Form S-8 and Form F-3, linking the product approval to the company’s broader capital markets documentation.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of 139,386 ordinary shares of Sol-Gel Technologies Ltd (SLGL), representing 5.00% of the class based on 2,785,787 shares outstanding. The shares are held by the Fund with voting and dispositive power shared among the reporting persons; no sole voting or dispositive power is reported. The filing states the stake was not acquired to change or influence control of the issuer and includes a joint filing agreement signed by James Silverman.